Home 9 Home video 9 Ep.6 – Real-world experience with SGLT-2 inhibitor use – Prof Michael Böhm

Ep.6 – Real-world experience with SGLT-2 inhibitor use – Prof Michael Böhm

December 26, 2022

Episode 6 – Real-world experience with SGLT-2 inhibitor use – Prof Michael Böhm

We are joined by Professor Michael Böhm. He is the director of the Clinic for Internal Medicine III and Chief of Cardiology at the University of the Saarland in Germany.

He has a special interest in pathophysiology and treatment of heart failure and has been the principal investigator of several multicentre clinical trials. He has written more than 700 original papers, book chapters and review articles and is a past president of the German Society of Cardiology.

For this episode, we will explore some real-world examples of the use of empagliflozin.

Test your knowledge Ep.6

1) Many patients do not take or tolerate their heart failure treatment regimen. Which of the following benefits do SGLT-2 inhibitors provide to overcome some previous challenges experienced by patients?

2) In patients hospitalised with acute heart failure and in the absence of contraindications, how soon after admission to hospital should SGLT-2 inhibitor treatment be initiated?

“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”.

“Not intended for US & UK based healthcare professionals”.

Available now to stream on your favourite platform: